A LinkedIn post from Field Medical Inc highlights the company’s planned participation in the PFA Live Summit at HRS2026 in Chicago. The post notes a featured session on ventricular tachycardia ablation using high-voltage, focal force-sensing pulsed field technology, presented by electrophysiologist Vivek Reddy, M.D.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post also emphasizes that the FieldForce™ PFA System remains an investigational device, limited by U.S. federal law to investigational use. For investors, this suggests Field Medical is actively positioning its technology within the electrophysiology and medtech community, but revenue generation from this platform is likely dependent on future clinical data, regulatory progress, and eventual commercialization.
Participation in a major specialty congress such as HRS2026 may help the company build physician awareness and potential key-opinion-leader support around its PFA approach. If the underlying data and performance of FieldForce™ prove favorable over time, this type of conference visibility could support future adoption curves and strengthen the firm’s competitive stance in the evolving pulsed field ablation market.